Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.
Wenzel M HackengLodewijk A A BrosensJoo Young KimRoderick O'SullivanYou-Na SungTa-Chiang LiuDengfeng CaoMichelle HeaynJacqueline Brosnan-CashmanSoyeon AnFolkert H M MorsinkCharlotte M HeidsmaGerlof D ValkMenno R VriensEls Nieveen van DijkumG Johan A OfferhausKoen M A DreijerinkHerbert ZehAmer H ZureikatMelissa HoggKenneth LeeDavid GellerJ Wallis MarshAlessandro PanicciaMelanie OngchinJames F PingpankNathan BaharyBrendan GillRandall BrandJennifer ChennatRohit DasKenneth E FasanellaAsif KhalidKevin McGrathSavreet SarkariaHarkirat SinghAdam SlivkaMichael NalesnikXiaoli HanMarina N NikiforovaRita Teresa LawlorAndrea MafficiniBoris RusevVincenzo CorboClaudio LuchiniSamantha BersaniAntonio PeaSara CingarliniLuca LandoniRoberto SalviaMassimo MilioneMichele MilellaAldo ScarpaSeung-Mo HongChristopher M HeaphyAatur D SinghiPublished in: Gut (2021)
ATRX/DAXX and ALT should be considered in the prognostic evaluation of NF-PanNETs including ≤2.0 cm tumours, and are highly specific for pancreatic origin among NET metastases of unknown primary.